AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06382129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06624072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 2
Description: when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
Study NCT06681662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine Hydrochloride 30 mg/ml
Description: 0.15 mg/kg during induction.
Study NCT06681662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: 1 ml during induction.
Study NCT06624670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion
Study NCT06624670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to spesolimab
Description: Placebo matching to spesolimab
Study NCT06624670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone
Study NCT06624670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone
Study NCT06624670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone
Study NCT06624670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone
Study NCT05625490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 Galmydar
Description: Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.
Study NCT05625490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13N-ammonia
Description: Two intravenous injections of PET radiotracer \[13N\]Ammonia.
Study NCT06051617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: * Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis.
Study NCT06051617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for up to 36 months.
Study NCT05369949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX group
Description: Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
Study NCT05369949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
Study NCT04593953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLIP
Description: Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
Study NCT05042752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CLINICAL ULTRASOUND
Description: The intervention group will receive the standard care of treatment in AHF and the performance of CU.
Study NCT05305859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax combining chidamide and azacitidine (VCA)
Description: information already included in arm/group descriptions
Study NCT05132660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Description: 25 mg carbidopa/100 mg levodopa
Study NCT05132660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill of similar size/shape
Study NCT05783947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera
Description: Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
Study NCT05926843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation surgery (device) and motor rehabilitation
Description: The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
Study NCT06317324 — intervention group
Intervention type: OTHER
Intervention: Different treatments
Description: NSCLC patients receive the treatment of SBRT
Study NCT04958577 — intervention group
Intervention type: DEVICE
Intervention: Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)
Description: This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.
Study NCT06778148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient AI for clinician documentation
Description: Ambient AI for clinician documentation
Study NCT06777641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote supervision
Description: teacher use remote supervision to assist peer training
Study NCT06092320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation on Pediatric Status Epilepticus
Description: The participants will complete a simulation session and debrief lead by a pediatric emergency medicine physician on status epilepticus.
Study NCT06092320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic Lecture on Pediatric Status Epilepticus
Description: The participants will complete a lecture on pediatric status epilepticus
Study NCT01845506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory monitor
Description: Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
Study NCT01845506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless pressure sensor
Description: Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
Study NCT05278819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity elevation
Description: 5 repetitions of active upper extremity elevation in a sitting position
Study NCT05278819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity elevation with deep breathing
Description: 5 repetitions of active upper extremity elevation with deep breathing in a sitting position
Study NCT06238635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
Study NCT06238635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab
Description: Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
Study NCT06319742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Extracellular vescicles (EV) analysis
Description: The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed.
Study NCT05778942 — intervention group
Intervention type: DEVICE
Intervention: Eyestil SYNFO
Description: Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
Study NCT05260879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes prevention program
Description: Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali
Study NCT05866042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
Study NCT05616299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightPoint
Description: Data from the BrightPoint device during epidural placement will be collected in real time on a tablet with pre-programmed software including tissue color and light reflectance with time stamps of when epidural space is entered as voiced by clinician per LOR.
Study NCT04968431 — intervention group
Intervention type: OTHER
Intervention: 2D Echocardiography
Description: Mitral valve area will be determined by 2 D echo-Doppler methods
Study NCT04968431 — intervention group
Intervention type: OTHER
Intervention: 3D Echocardiography
Description: Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
Study NCT06001645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and bronchoalveolar fluid collection and analysis
Description: Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
Study NCT06001645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT scan
Description: Computed Tomography Scan per normal clinical practice
Study NCT04763226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986308
Description: Specified dose on specified days
Study NCT04763226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (for BMS-986308)
Description: Specified dose on specified days
Study NCT04763226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Specified dose on specified days
Study NCT06240819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleeper Stretch
Description: They will receive three sessions a week for four weeks. In a session three sets with three repetitions of sleeper stretch in a side lying position
Study NCT06240819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cross Body Stretch
Description: They will receive three sessions a week for four weeks. In a session, three sets with three repetitions of cross-body stretch will be done in sitting position.
Study NCT05976139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subthreshold treatment with micropulsed laser
Description: The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~* Power: 5% Duty Cycle~* Power 250 mw~* Pulse duration 200 ms~* Spot size 100 micron~* Pattern spacing 0.0 confluente, griglie 7x7
Study NCT05005962 — intervention group
Intervention type: DEVICE
Intervention: Neurothrombectomy
Description: Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
Study NCT06273813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 15 MG/ML
Description: Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
Study NCT06273813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Three doses of topical ketorolac tromethamine over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods in cohort 1 Three doses of Ketorolac Tromethamine, 6 hours apart, over the course of 5 days in cohorts 2 and 3
Study NCT05463497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A
Description: JW0201: single administration, Tablet, Oral, BID for 5 days
Study NCT05463497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B
Description: C2103: single administration, Tablet, Oral, BID for 5 days
Study NCT05463497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment C
Description: JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
Study NCT05463497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment D
Description: C2104 : single administration, Tablet, Oral, QD for 5 days
Study NCT05463497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment E
Description: JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
Study NCT06431529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor neoantigen specific T cell
Description: Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).
Study NCT04708951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOCUFF VISION® device
Description: ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
Study NCT04708951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE® colonoscope
Description: The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
Study NCT05963945 — intervention group
Intervention type: DEVICE
Intervention: Carebot AI CXR
Description: The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
Study NCT05083910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin administration
Description: Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
Study NCT05510050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Vera Extract 1
Description: 2 capsules taken daily for 30 days
Study NCT05510050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 2 capsules taken daily for 30 days
Study NCT05510050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aloe Vera Extract 2
Description: 2 capsules taken daily for 30 days
Study NCT05442684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
Description: Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
Study NCT05442684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation
Description: Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
Study NCT05442684 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-based COVID-19 vaccine
Description: Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
Study NCT04687904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Description: Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
Study NCT05353075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub Occipital Muscle Inhibition
Description: The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.